Essential Premium

From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory

A spring pivot in sentiment turned one of the sector’s toughest stretches into a breakout year for the specialist funds.

The Numbers Are in on Short Sellers’ Losing Year

Nvidia was the shorts’ biggest loser, but they profited on companies like Apollo and UnitedHealth.

Sponsored

Portfolio Finance: 101

Caxton and Graham Post Solid Gains in a Strong Year for Macro Funds

Double-digit returns for Caxton and steady gains for Graham underscore a year when many macro managers capitalized on big market moves.

Related Content

Janus Henderson Maintains Its Wide Lead in Biotech

Steve Taub

Ali Dibadj Can Take the Jokes, But He Wants to Talk Seriously About Janus Henderson

Michael Thrasher

Biopharma Hedge Funds Are in a Tailspin

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram